ArticleClinical rheumatology2026
Residual symptom absence assessed by Okomarigoto Sheet is independently associated with patient-acceptable symptom state beyond inflammation in rheumatoid arthritis.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTelemedicine has expanded rapidly, increasing reliance on patient-reported outcome measures (PROMs) for disease assessment in rheumatoid arthritis (RA). However, conventional PROMs may inadequately capture residual symptoms, resulting in discordance between inflammatory control and patient-perceived burden. The Okomarigoto Sheet (OS) was developed to evaluate residual symptoms. This study assessed the clinical relevance of the OS as a complementary tool to conventional PROMs in RA.
methodsThis cross-sectional, single-center study included patients with RA. Residual symptoms were evaluated using OS, and patient-acceptable symptom state (PASS) was assessed using the current PASS framework. Associations between OS and Routine Assessment of Patient Index Data 3 (RAPID3) were examined, and the proportion of OS = 0 was compared across RAPID3 categories. Multivariate logistic regression was performed to identify factors associated with PASS nonachievement, including OS = 0, RAPID3, and Simplified Disease Activity Index (SDAI) remission.
resultsAmong 363 patients, the total OS score correlated with RAPID3 (r = 0.632, p < 0.001); however, residual symptoms persisted even in low disease activity. In multivariate analyses, an OS = 0 was independently associated with a lower likelihood of PASS nonachievement (OR = 0.23, p = 0.002), along with SDAI remission (OR = 0.10, p < 0.001). RAPID3 was not significant after adjustment. Model fit improved with OS inclusion.
conclusionsThe OS provided complementary information beyond RAPID3 and remained independently associated with PASS after adjustment for inflammation. Patient acceptability depends not only on inflammatory control but also on the resolution of residual symptoms. Incorporating the OS may enhance patient-centered evaluation, including telemedicine settings. Key Points • Residual symptom absence independently determines patient-acceptable symptom state beyond inflammatory control. • RAPID3 alone may underestimate residual symptoms relevant to patient-perceived disease burden. • Okomarigoto Sheet complements conventional measures by detecting clinically meaningful residual symptoms.
Indexed as
Identifiers
42342982What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.